Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Children's Hospital of Fudan University
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05925309CT.gov Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cholangitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Imipenem (this asset) | Children's Hospital of Fudan University | N/A | D · 30 |
| Ceftriaxone | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P4 | BB |
| L-Ofloxacin | University of Southern California | P4 | BB |
| Normal Human Serum Albumin | EASL - CLIF Consortium | P4 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Ankara City Hospital Bilkent | P2 | B |
| Meperidine | National University of Malaysia | P2 | B |
| Moxifloxacin | Kangbuk Samsung Hospital | P2 | B |
| htd1801 | HighTide Biopharma Pty Ltd | P2 | B |
| Midazolam | National University of Malaysia | P2 | B |
+11 more in the Cholangitis cohort
Other indications for Imipenem
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bacterial Pneumonia | — | P4 | BB · 65 |
| Cystic Fibrosis | — | P4 | B · 59 |
| Cirrhosis Of Liver | — | P4 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Imipenem in Cholangitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/imipenem-cholangitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →